Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data
Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.
Viking stock drops 13% after jumping 9% on obesity drug data
Viking (VKTX) stock fell 13% Monday afternoon after jumping 9% earlier in the day amid concerns the company might face production problems for its obesity drug candidate VK2735.
Viking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety
Viking Therapeutics highlights VK2735's promising weight loss data at ObesityWeek 2024, with up to 14.7% reduction and improved prediabetic outcomes.
Viking Therapeutics Stock Climbs On Positive Data From VK2735 Obesity Program
Shares of Viking Therapeutics, Inc. (VKTX) were gaining around 17 percent in the pre-market activity on the Nasdaq after the company
Viking Therapeutics soars as early-stage oral obesity drug data exceeds expectations
Viking Therapeutics shares surged 25% before the bell on Monday after early-stage data from the company's experimental oral obesity drug showed weight loss and safety above Wall Street expectations. Patients who received the higher dose 100 milligram version of the oral drug,
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term prospects remain positive.
Promising Phase 1 Results for Viking Therapeutics’ VK2735: Analyst Recommends Buy Rating
Michael Ulz, an analyst from Morgan Stanley, reiterated the Buy rating on Viking Therapeutics (VKTX – Research Report). The associated
bovnews1d
Viking Therapeutics Inc (VKTX) Stock: More Resilient Than It Appears
On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $64.63 which represents a slight increase of $1.49 or 2.36% from the prior close of $63.14. The stock opened at ...
Viking Therapeutics (VKTX) Gets a Buy from Truist Financial
Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company’s shares closed last Friday at $72.88. Lee covers ...
Should you buy Viking Therapeutics (VKTX) after today’s spike?
Viking Therapeutics (VKTX) surges on promising obesity drug results. Explore key price levels and analyst insights in this detailed analysis.
bovnews13d
The VKTX Stock Mystery: Why Did VKTX Surge Today?
On Thursday, Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $73.22 which represents a slight increase of $12.83 or 21.25% from the prior close of $60.39. The stock opened ...
SchaeffersResearch.com3d
Biotech Stock Reverses Gains Despite Obesity Pill Buzz
Viking Therapeutics (VKTX) stock is reversing gains despite earlier announcing strong results for its experimental obesity pill ...
ETF Daily News10d
What is William Blair’s Forecast for VKTX FY2024 Earnings?
Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) – Analysts at William Blair lowered their FY2024 earnings per share (EPS) estimates for shares of Viking Therapeutics in a research report ...
Nasdaq9d
VKTX Quantitative Stock Analysis
Below is Validea's guru fundamental report for VIKING THERAPEUTICS INC (VKTX). Of the 22 guru strategies we follow, VKTX rates highest using our P/B Growth Investor model based on the published ...
Viking Therapeutics participates in a conference call with JPMorgan
Conference call with CEO Dr. Lian and CFO Zante to be held on November 5 at 11:30 am hosted by JPMorgan. Webcast Link Published first on ...